Sonoma Pharmaceuticals enters two distribution deals for Microcyn products

Sonoma Pharmaceuticals, Inc.

Non-exclusive distribution with Salus Medical for Microcyn dental/derm/wound/eye care in US; one-year initial term.
Exclusive license to Anlicare for dental/oral products in China and Macau; five-year term after regulatory approval.
Anlicare pays milestones-based royalties; must obtain regulatory licenses within two years or deal terminates.
Salus can sell via own website only; no third-party platforms like Amazon.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.